Summary & Overview
CPT 38212: HPC Product Preparation with Red Blood Cell Depletion
CPT code 38212 describes the preparation of hematopoietic progenitor cell (HPC) products with maximal removal of red blood cells to reduce transplant complications, a critical step for marrow and cryopreserved cell transplants. Nationally, this procedure is central to safe hematopoietic stem cell transplantation programs and impacts clinical workflows, laboratory staffing, and facility billing practices. Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical and billing context for 38212, an overview of common payer coverage patterns and reimbursement considerations, and the clinical rationale for aggressive red cell depletion in HPC products. The publication also outlines typical sites of service and how this code fits into transplant episode billing. Data not available in the input is noted where applicable. This piece serves clinicians, transplant program administrators, and billing professionals seeking a national summary of the code's purpose, payer landscape, and implications for transplant laboratory operations.
Billing Code Overview
CPT code 38212 describes preparation of a hematopoietic progenitor cells (HPCs) solution with removal of the greatest number of red blood cells to minimize transplant complications, particularly when transplanting cryopreserved cells such as marrow.
-
Service type: Cell product preparation focused on red blood cell depletion
-
Typical site of service: Hospital laboratory or transplant center laboratory performing cellular therapy product processing
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with relapsed acute myeloid leukemia undergoes autologous hematopoietic progenitor cell (HPC) transplantation. After collection and cryopreservation of marrow-derived HPCs, the transplant team prepares the graft in the laboratory to minimize red blood cell (RBC) content before infusion to reduce hemolytic and volume-related complications. The clinical workflow begins with receipt of the cryopreserved HPC bag(s) in the cellular therapy laboratory, thawing if indicated, followed by RBC reduction techniques such as centrifugation, gradient separation, or automated cell processing to produce a cell suspension with reduced erythrocytes. The processing is documented in the laboratory record, including cell counts, viability, final volume, and any quality control testing. The prepared HPC product is then released to the transplant service for infusion in the inpatient bone marrow transplant unit or outpatient infusion center, with communication of processing details to the transplant physician and nursing team.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or resources to perform HPC red cell reduction are substantially greater than typical and well documented. |
52 |